Pinealon

Pinealon is Glu-Asp-Arg, a tripeptide from Vladimir Khavinson's short-peptide programme at the St Petersburg Institute of Bioregulation and Gerontology — the same programme that produced Epitalon and Cartalax. In that literature it is usually called the EDR peptide and it is presented as the brain's bioregulator, studied for neuroprotection, hypoxia tolerance and age-related cognitive decline [5].

The cell work is the strongest part. In a 2011 paper in Rejuvenation Research, pinealon produced dose-dependent restriction of reactive oxygen species in cerebellar granule cells, neutrophils and PC12 cells under both receptor-dependent and receptor-independent oxidative stress, and reduced necrotic cell death. The protection came with a delayed ERK1/2 time course and a modified cell cycle — and because the cell-cycle effect kept increasing at concentrations where the antioxidant effect had already saturated, the authors concluded the peptide acts on the genome directly as well as on radicals [1]. Separately, fluorescently labelled pinealon was found in the nucleus and nucleolus of HeLa cells and bound CNG- and CAG-containing oligonucleotides selectively, discriminating even their methylation status [2].

The animal work is mixed, and the mixture is informative. Against hypobaric hypoxia, pinealon was the most active of four short peptides tested [6]. Under acute hypoxic hypoxia in old rats it was described as increasing neurogenesis and returning neuroinflammatory markers towards reference values [7]. But in a head-to-head with Cortexin under hypoxia and hypothermia, Cortexin had the more pronounced effect on free-radical processes and caspase-3 [8]. And in old rats dosed before carotid artery occlusion, the result was two-sided: survival improved, but behavioural sleep time went up while position-finding, motivational behaviour and motor performance all went down, and caspase-3 activity rose moderately in the brain of both operated and sham animals [3]. A further study of peptide geroprotectors looked at navigation learning and caspase-3 across ages [9].

The human evidence is one study. Thirty-two people aged 41 to 83 with chronic polymorbidity and organic brain syndrome in remission were given Pinealon or Vesugen. The authors report a significant anabolic effect and improved central nervous system activity, slowing the rate of ageing on biological-age indicators — and they also report that Vesugen did more than Pinealon, that chemiluminescence showed prooxidant activity, and that circulating CD34+ haematopoietic cells fell, which they interpreted as significant inhibition of haemopoiesis. Chromatin condensation was unaffected, which they took as reassurance at the nuclear genetic level [4]. There is no control group described in the abstract, the article is in Russian, and no dose is given.

The 2020 review states that the EDR peptide "improves memory issues in elderly patients" [5]; the study above is the kind of evidence that statement rests on.

The proposed mechanism is the one shared across this family of peptides: small enough to enter the cell and the nucleus, binding chromatin and nucleic acids in a sequence-selective way, and changing which genes are transcribed [2][10].

For pinealon specifically, the 2020 review assembles a long downstream list — MAPK/ERK signalling, the proapoptotic proteins caspase-3 and p53, the antioxidant enzymes SOD2 and GPX1, the transcription factors PPARA and PPARG, serotonin and calmodulin — and notes that the peptide prevents the elimination of dendritic spines in neuronal cultures from mice with Alzheimer's and Huntington's models [5]. It is proposed to bind histones and RNA to do this. The same general framework has been set out for the whole peptide family [10][11][12].

Two gaps are worth naming. The list of affected proteins is largely a list of things measured after treatment, not a demonstrated chain of causation from a binding event. And the whole scheme requires an injected or swallowed tripeptide with free termini to survive peptidases, cross membranes and reach chromatin — which has been shown for labelled peptide added to cells in a dish [2] and never in a living animal, because no pharmacokinetic study exists.

There is also a real tension inside the mechanism. The cell work has pinealon suppressing ROS and necrosis [1]; the single human study found prooxidant activity by chemiluminescence and classified the peptide as a geroprotector of the "anabolic neuroprotective and no antioxidant type" [4]. Those are not the same picture.

Pinealon is the free tripeptide Glu-Asp-Arg, molecular weight 418, supplied lyophilised. In Russia it is marketed both as an injectable and as an oral capsule product; the research literature uses injected routes in animals and does not report an absorption study for either form.

The peptide is one of a numbered family designed on the same principle — Vesugen (Lys-Glu-Asp), Testagen (Lys-Glu-Asp-Gly), Bronchogen (Ala-Glu-Asp-Leu), Epitalon (Ala-Glu-Asp-Gly) — and the DNA-binding study compared several of them side by side, finding that the sequence determines which oligonucleotide motifs they prefer [2].

No adverse events are reported in the animal literature, and the human study reported none directly. What it did report deserves more attention than it usually gets.

In 32 patients, the authors found prooxidant activity by chemiluminescence, and a decrease in circulating CD34+ haematopoietic polypotent cells that they described as significant inhibition of haemopoiesis — noting the cells "have not been involved in the adaptive reactions". They found no effect on chromatin condensation and concluded the peptides are safe at the nuclear genetic level, while recommending that the haemopoietic finding be studied further [4]. That is an author-flagged open question in the only human study there is.

The rat carotid occlusion study is the other thing to weigh: survival improved, but the treated animals did worse on position-finding, motivational behaviour and motor performance, and brain caspase-3 — a measure of apoptotic machinery — rose moderately [3].

Beyond that, the usual limits of this category apply. No pharmacokinetics in any species. No long-term data. No independent replication of anything, and a literature concentrated in Advances in Gerontology and a small number of related journals, largely in Russian.

No interaction studies exist. In the human study Pinealon was compared with, not combined with, Vesugen [4], and in the rat work it was compared with Cortexin rather than given alongside it [3][8].

Nothing documents an interaction with any compound on this site.